Incretin Based Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Incretin Based Drugs Market Analysis
The incretin-based drugs market is expected to register a CAGR of 5.2% during the forecast period.
Initially, COVID-19 impacted the incretin-based drugs market in its initial phase due to the cancellation of elective procedures for chronic diseases, including diabetes. However, the virtual consultations for diabetes and rising awareness about the management of diabetes allowed patients to continue their incretin-based drug medication. COVID-19 also had an adverse impact on people with diabetes. For instance, according to an article published in the Journal of Pharmacy Practice in May 2022, COVID-19 was associated with a high mortality risk among diabetes mellitus (DM) patients. The studied market is expected to remain unaffected by the emergence of new variants of COVID-19 and is further expected to show a significant growth rate during the forecast period.
The incretin-based drugs market is expected to grow during the forecast period owing to the high burden of Type- 2 diabetes globally. For instance, as per the International Diabetes Federation (IDF) 2021 report, the number of adults (20-79 years) with diabetes was 536.6 million in 2021 and is predicted to reach 783.2 million by 2045. The prevalence of diabetes worldwide was 10.5% in 2021 and is projected to be 12.2% in 2045. The high burden of diabetes requires an incretin-based drug for normalizing blood glucose levels, thereby propelling market growth.
Furthermore, according to the Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, data published in May 2022, the obesity prevalence was 39.8% among adults aged 20 to 39 years, 44.3% among adults aged 40 to 59 years, and 41.5% among adults aged 60 and older. Obesity is one of the most important factors which are expected to drive the incidence of diabetes. Therefore, the high burden of obesity worldwide is also expected to drive market growth during the forecast period.
Additionally, as per a Statpearls article updated in August 2022, DPP-4 inhibitors are also called gliptins, a class of oral diabetic medications approved by the Food and Drug Administration (FDA) to treat type 2 diabetes mellitus in adults. The FDA-approved DPP-4 includes sitagliptin, saxagliptin, linagliptin, and alogliptin. Vildagliptin has approval from the European Medicines Agency (EMA) but not from the FDA. Therefore, the large number of available approved DPP-4 creates an opportunity for market players to manufacture and market incretin-based drugs during the forecast period.
Therefore, owing to the factors such as the high burden of diabetes and rising approvals of DPP-4, and advantages offered by the drugs in the management of diabetes, the studied market is anticipated to witness growth over the analysis period. However, lack of reimbursement and poor accessibility to drugs, especially in developing countries, are the factors expected to restrain the market growth during the forecast period.
Incretin Based Drugs Market Trends
This section covers the major market trends shaping the Incretin Based Drugs Market according to our research experts:
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Holds Significant Share in the Global Incretin-Based Drugs Market
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. Examples of drugs in this class include exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide. The segment is expected to grow during the forecast period owing to the high burden of diabetes, and obesity, rising research activities, and product launches and approvals by market players.
According to a Statpearls article updated in November 2022, the addition of a GLP-1 analog should be considered in patients with a metformin contraindication or intolerance, in patients with a hemoglobin A1c greater than 1.5% above target, or in patients who do not reach their target A1c in three months, especially in patients with atherosclerosis, heart failure, or chronic kidney disease. Therefore, the advantage of GLP-1 in metformin-resistant patients is expected to propel the demand for GLP-1 during the forecast period.
Furthermore, product approvals and launches by market players significantly add to the market growth. For instance, in May 2022, the US FDA approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes as an addition to diet and exercise. The rising approvals are expected to boost segment growth.
Therefore, the above-mentioned factors, such as the advantage of GLP-1 and rising approvals, the segment is expected to witness significant growth during the forecast period.
North America is Expected to Dominate the Incretin-Based Drugs Market Over the Forecast Period
North America is expected to dominate the market owing to factors such as the rising incidence of diabetes and obesity, product launches, and approvals, along with the high concentration of market players in the region.
As per IDF 2021 report, the number of adults (20-79 years) with diabetes in the North American region (including the United States, Canada, and Mexico) was 49.3 million in 2021. As per the same source, the number of diabetes in the North American region is predicted to reach over 55 million by 2030. The rising burden of diabetes in the region is expected to propel the demand for needle-free insulin delivery devices, thereby augmenting market growth.
Furthermore, according to the World Population Review 2022 data, around 29.4% of the people in Canada were affected by obesity. The high burden of obesity in the region is associated with a high probability of developing type-2 diabetes during the forecast period, thereby propelling the market growth.
Additionally, the strategic initiatives adopted by market players, such as product approvals, launches, and partnerships to expand the offerings, are expected to propel the market growth. For instance, in December 2021, the Food and Drug Administration approved the second biosimilar insulin product, Eli Lilly's Rezvoglar (insulin glargine-aglr). Rezvoglar (insulin glargine-aglr) is biosimilar to Lantus (insulin glargine). Also, in July 2021, the United States Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.
Therefore, owing to the above-mentioned factors, such as the high burden of diabetes and obesity, rising product approvals, and launches by market players, the growth of the studied market is anticipated in the North America Region.
Incretin Based Drugs Industry Overview
The incretin-based drugs market is moderately competitive. Some key players are AstraZeneca, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly, GlaxoSmithKline PLC., Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, and Sanofi SA, among others, hold the major share in the market.
Incretin Based Drugs Market Leaders
-
AstraZeneca
-
Novo Nordisk
-
Eli Lilly
-
Novartis AG
-
Merck & Co. Inc.
*Disclaimer: Major Players sorted in no particular order
Incretin Based Drugs Market News
- April 2022: Glenmark Pharmaceuticals Limited launched a novel fixed-dose combination (FDC) of DPP4 inhibitor, Teneligliptin, with Pioglitazone. This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes.
- January 2022: Novo Nordisk launched oral semaglutide in India to treat type 2 diabetes.
Incretin Based Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definitions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Obsesity and Diabetes
4.2.2 Growing Awareness and R&D Activities
4.3 Market Restraints
4.3.1 Lack of Reimbursement
4.3.2 Poor Accessibility to Drugs Especially in Developing Countries
4.4 Porter Five Forces
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug Type
5.1.1 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
5.1.2 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injectable
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Boehringer Ingelheim Pharmaceuticals, Inc.
6.1.3 Eli Lilly
6.1.4 GSK Plc
6.1.5 Merck & Co., Inc.
6.1.6 Novartis AG
6.1.7 Novo Nordisk
6.1.8 Sanofi
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Incretin Based Drugs Industry Segmentation
As per the scope of the report, incretin-based treatments control post-meal glucagon and help reduce post-meal blood sugars. These medicines also refer to blood sugar normalizing medications or euglycemic, i.e., drugs that help retain the blood sugar to the normal range. The incretin-based medicines are available in two families of medicines, i.e., DPP-4 Inhibitors and GLP-1 analogs. The Incretin-based Drugs Market is Segmented by Drug Type (Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors), Route of Administration (Oral and Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Drug Type | |
| Glucagon-like Peptide-1 (GLP-1) Receptor Agonists | |
| Dipeptidyl Peptidase-4 (DPP-4) Inhibitors |
| By Route of Administration | |
| Oral | |
| Injectable |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Incretin Based Drugs Market Research FAQs
What is the current Incretin-based Drugs Market size?
The Incretin-based Drugs Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Incretin-based Drugs Market?
AstraZeneca , Novo Nordisk , Eli Lilly , Novartis AG and Merck & Co. Inc. are the major companies operating in the Incretin-based Drugs Market.
Which is the fastest growing region in Incretin-based Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Incretin-based Drugs Market?
In 2024, the North America accounts for the largest market share in Incretin-based Drugs Market.
What years does this Incretin-based Drugs Market cover?
The report covers the Incretin-based Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Incretin-based Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Incretin-based Drugs Industry Report
Statistics for the 2024 Incretin-based Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Incretin-based Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
